Kratom’s alkaloids interact with a surprisingly wide range of receptors in the body, though their primary target is the mu-opioid receptor. The plant contains over 40 alkaloids, but two do most of the pharmacological heavy lifting: mitragynine, which makes up roughly two-thirds of the alkaloid content, and 7-hydroxymitragynine, a minor but far more potent compound. Together with several lesser alkaloids, they bind to opioid, serotonin, adrenergic, and glutamate receptors, creating a complex pharmacological profile that doesn’t neatly fit into any single drug category.
Mu-Opioid Receptors: The Primary Target
Mitragynine binds to the mu-opioid receptor with a Ki value of about 709 nM. That’s the same receptor morphine and fentanyl activate, but mitragynine’s grip on it is roughly 89 times weaker than morphine’s and far weaker than fentanyl’s. It does show selectivity for this receptor over the other two opioid subtypes: its affinity for mu receptors is about 2.4 times stronger than for kappa-opioid receptors and nearly 10 times stronger than for delta-opioid receptors.
7-Hydroxymitragynine is a different story. Present in much smaller quantities in the raw leaf, it binds mu-opioid receptors with a Ki between roughly 7 and 70 nM depending on the assay, placing it in the same general potency neighborhood as morphine. In functional tests measuring pain relief in animals, 7-hydroxymitragynine has shown approximately 13-fold greater potency than morphine and 46-fold greater potency than mitragynine. The FDA has flagged this compound specifically as an opioid threat because of its high affinity and full agonist activity at mu receptors, along with its ability to produce respiratory depression at doses more than three times as potent as morphine.
G-Protein Biased Signaling at Opioid Receptors
What makes kratom’s opioid receptor activity unusual is how it activates those receptors. When a traditional opioid like morphine binds the mu receptor, it triggers two main signaling cascades: one through G proteins (which produces pain relief) and another through a molecule called beta-arrestin (which is linked to side effects like respiratory depression and constipation). Mitragynine and 7-hydroxymitragynine activate the G-protein pathway but produce no measurable beta-arrestin recruitment, even under conditions designed to amplify that signal.
This “biased agonism” is significant because pharmaceutical companies have spent years trying to engineer opioids that selectively activate G-protein signaling while avoiding beta-arrestin. Kratom’s alkaloids do this naturally. In practical terms, this may help explain why kratom use appears to carry a lower risk of fatal respiratory depression compared to classical opioids, though it does not make the compounds risk-free.
Adrenergic Receptors
Beyond the opioid system, mitragynine interacts with the adrenergic receptors that respond to adrenaline and noradrenaline. At alpha-2A adrenergic receptors, mitragynine acts as a competitive antagonist, blocking the receptor rather than activating it. This means it opposes the calming, blood-pressure-lowering effects that drugs like clonidine produce at these same receptors. The antagonism is consistent across multiple signaling pathways tested in human cells.
At alpha-1A adrenergic receptors, mitragynine does the opposite: it behaves as a weak partial agonist, gently activating one specific signaling pathway. Both interactions occur at low potency (requiring micromolar concentrations), so their real-world significance at typical kratom doses is still being worked out. However, these adrenergic effects likely contribute to kratom’s stimulant-like properties at low doses, including increased alertness and energy that users commonly report.
Serotonin Receptors
Some of kratom’s most interesting non-opioid activity involves the serotonin system, and here the minor alkaloids take center stage. Paynantheine and speciogynine, two alkaloids present in smaller quantities, bind serotonin 5-HT1A receptors with Ki values around 32 and 38 nM respectively. That’s a high affinity, considerably stronger than mitragynine’s own binding at that site (Ki of about 5,800 nM). Both alkaloids also bind 5-HT2B receptors with similarly high affinity, around 20 to 23 nM.
In animal studies, paynantheine and speciogynine produced behaviors characteristic of serotonin 5-HT1A receptor activation, including lower lip retraction (a marker used in rats) and pain relief that could be blocked by a selective 5-HT1A antagonist. This suggests the pain-relieving properties of whole kratom leaf aren’t solely opioid-driven. The serotonin component may also explain some of kratom’s reported mood-lifting effects.
Interestingly, despite binding tightly to these serotonin receptors, neither paynantheine nor speciogynine activated the standard G-protein signaling cascade in cell-based assays. They bind the receptor without triggering the classic “on switch,” which could mean they act through alternative signaling mechanisms or function as modulators that change how the receptor responds to the body’s own serotonin.
Glutamate Receptors
Mitragynine also appears to interact with the glutamate system, the brain’s primary excitatory signaling network. Studies on brain tissue from the hippocampus (a region involved in learning and memory) found that mitragynine mildly inhibits synaptic plasticity in a pattern resembling weak antagonism at both AMPA and NMDA receptors. These are the receptors responsible for strengthening connections between neurons.
The effect is described as mild, but it’s worth noting because NMDA receptor antagonism is a property shared by drugs like ketamine and dextromethorphan. At the low functional potency observed, this activity could contribute to kratom’s reported dissociative or “dreamy” quality at higher doses without producing the intense dissociation associated with dedicated NMDA antagonists.
Minor Alkaloids at Opioid Receptors
Three of kratom’s secondary alkaloids, speciociliatine, speciogynine, and paynantheine, also interact with the mu-opioid receptor, but as low-potency competitive antagonists rather than agonists. They block the receptor instead of activating it, and none of them show meaningful activity at kappa or delta opioid receptors. This is pharmacologically unusual: a single plant producing both opioid agonists and opioid antagonists. The balance between these compounds in any given kratom product could influence the overall effect, potentially explaining why different strains or batches produce noticeably different experiences.
Drug Metabolism Interactions
Kratom’s receptor activity isn’t its only pharmacological concern. Mitragynine strongly inhibits CYP2D6, a liver enzyme responsible for breaking down about 25% of all prescription drugs, with an IC50 of just 0.45 micromolar. It also moderately inhibits CYP2C9 (IC50 of 9.7 micromolar) and weakly inhibits CYP3A4 (IC50 of 41.3 micromolar). This means kratom could slow the metabolism of many common medications, effectively increasing their concentration in the blood. Drugs processed by CYP2D6 carry the highest risk of interaction, and this category includes many antidepressants, antipsychotics, beta-blockers, and some pain medications.